Project Grant RM1DA064594
- Federal Grant Award Summary Yale University received a $1.38 million Project Grant from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) awarded June 1, 2025, with completion targeted for February 28, 2030. The project, titled "Applying a Multiple Methods Approach to Examine Spatial and Temporal Variability in a State's Illicit Drug Market," delivers integrated data collection and analysis on drugs circulating in Connecticut's...
- Federal Project Grant Award Summary Yale University received a $158,545 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), effective March 1, 2026 through February 29, 2028. This award supports the community pharmacy-based adaptation and pilot testing of integrated HIV and substance use disorder (SUD) care. The project, led by Dr. Tarfa (a pharmacist and health services researcher at Yale School of Medicine), addresses...
- Federal Project Grant Award Summary Yale University received a $336,250 project grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), effective April 1, 2026 through March 31, 2028. The award supports the development of a behavioral foundation model that leverages advanced natural language processing and large language models to transform qualitative epidemiological survey responses from the National Epidemiologic Survey on...
- Federal Grant Award Summary Yale University received a $2.26 million Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) awarded March 1, 2026, with completion targeted for February 28, 2030. The award funds research to characterize genetic effects on molecular phenotypes at single-cell resolution across brain regions in the context of substance use disorder (SUD) and HIV comorbidity. The project leverages data from...
- Federal Project Grant Award Summary Yale University received a $195,048 Project Grant from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279), effective September 1, 2025 through August 31, 2030. This award supports the development of a culturally adapted Contingency Management (CM) intervention for adults with Stimulant Use Disorder in New Haven, Connecticut. CM is a behavioral economics-based intervention that uses tangible positive...
- Federal Grant Award Summary Yale University received a $1,551,100 Project Grant awarded on August 15, 2025, by the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a cluster randomized controlled trial evaluating the HOPE (Help OAT Prison Engagement) intervention for HIV prevention in Kyrgyzstan's prison system. The research addresses critical public health needs in a high-risk environment where 10.3% of the 9,500 inmates are...
- Federal Project Grant Award Summary Yale University received a $1,061,526 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded May 15, 2025, with completion targeted for April 30, 2027. The award supports the design and testing of SPARC (Substance use Prevention in Adolescents Receiving Clinical decision supports), a novel health equity-focused clinical decision support intervention integrated into pediatric...
- Federal Grant Award Summary Yale University received a $357,613 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) effective June 1, 2025, through May 31, 2027. The award funds a research initiative titled "Finding the Missing Parts of Human Genetics of Substance Use Disorders," which leverages large-scale whole-genome sequencing (WGS) data from publicly available biobanks, including the All of Us...
- Federal Grant Award Summary Yale University received a $197,024 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) on July 30, 2025, with a completion date of June 30, 2027. The grant funds two multi-methods research studies examining the impact of xylazine, a veterinary tranquilizer emerging as an adulterant in the unregulated opioid supply, on people who use drugs (PWUD). The first study, conducted in North...
- Federal Grant Award Summary Yale University received a $3.14 million Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded May 1, 2025, with a completion date of February 28, 2030. The grant supports a comprehensive neuroimaging research initiative investigating kappa opioid receptors (KOR) in individuals with opioid use disorder (OUD) during early abstinence. The project delivers novel positron emission...
Yale University received a $2.23 million Project Grant from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279), effective April 1, 2026 through February 28, 2031. The GEO IMPACT project deliverables include development and implementation of a learning public health system designed to increase reach and access to HIV and substance use disorder prevention, care, and treatment services for people who use drugs (PWUD) in Connecticut. The project will deploy a novel mobile pharmacy and clinic (MPC) healthcare delivery model staffed with community health workers to serve high-risk populations. The project will deliver three primary service components: (1) population identification and needs assessment through collaboration with six Connecticut state health agencies to identify PWUD populations living with or at risk for HIV and quantify service needs using modeling techniques; (2) service alignment and deployment of the MPC to target geographic areas with evaluation of outcomes at macro, meso, and micro levels comparing implementation communities to matched control communities; and (3) optimization of healthcare delivery through mixed-methods, community-engaged research characterizing local barriers to care. These integrated services address the federal priority of supporting implementation research to expand evidence-based treatment access for underserved populations affected by converging HIV and substance use public health crises.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 4/16/26 | ||
| Not listed | $2.2m | 4/1/26 |